AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections

艾滋病毒及相关感染治疗研究艾滋病临床试验小组

• 批准号: 10395059
• 负责人: Judith S. Currier
• 金额: $ 2056.64万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-23 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10395059
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Address; Affect; Aging; Anti-Retroviral Agents; Antiviral Agents; Area; Behavioral; Biological Markers; Blood; California; Cardiovascular system; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Conduct Clinical Trials; Development; Disease; Disease remission; Drug resistance in tuberculosis; Epidemic; Evaluation; Funding; Goals; HIV; HIV Infections; HIV/TB; Health; Hepatitis B; Hepatitis B Virus; Immune; Immunologics; Industry Collaboration; Infection; Infrastructure; International; Intervention; Knowledge; Laboratories; Leadership; Los Angeles; Maintenance; Mental Health; Metabolic; Morbidity - disease rate; Multidrug-Resistant Tuberculosis; Neurologic; Obesity; Occupational activity of managing finances; Phase; Population; Prevention; Prevention and Treatment of Opportunistic Infection; Protocols documentation; Publishing; Regimen; Research; Research Personnel; Resources; Risk; Science; Specimen; Structure; System; Testing; Therapeutic; Therapeutic Intervention; Tissues; Training; Tuberculosis; Universities; Virus Diseases; active method; acute infection; antiretroviral therapy; burden of illness; chronic infection; collaboratory; community engagement; community involvement; comorbidity; comparative efficacy; data management; design; drug-sensitive; efficacy trial; improved; innovation; mortality; multidisciplinary; neutralizing antibody; novel; operation; prevent; protocol development; social; statistics; therapeutic vaccine; treatment guidelines; virology

Project Summary The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of people living with HIV/AIDS for 30 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG we propose a transformative research agenda that draws on an international consortium of leading clinical and laboratory HIV investigators in collaboration with a world-class Statistics and Data Management Center to design and conduct innovative interventional clinical trials that will significantly reduce the global burden of disease due to HIV, TB and hepatitis B. The Leadership and Operations Center (LOC) provides scientific leadership and fiscal and organizational management of the ACTG. The ACTG Executive Committee (AEC) will serve as the overarching governing body of the network. The AEC is guided by an Executive Management Committee that includes the Network Chairs, Chief Quality Officer and the Chairs of the Laboratory and Statistical and Data Management Centers. Transformative Science Groups will oversee the development and execution of the ACTG research agenda, which will be coordinated and prioritized by the Scientific Agenda Steering Committee (SASC). Protocol development, implementation, training and network evaluation will be facilitated by the Network Clinical Core at Social & Scientific Systems, Inc. The LOC financial management group (Admin Core) at the University of California, Los Angeles will oversee resource management and protocol fund distribution at the direction of the AEC. The LOC will assure the engagement of Community in all aspects of the ACTG, and will coordinate communication between all three components of the network. Specific aims of this proposal include: 1) Identify interventions to reduce HIV reservoirs and control HIV replication in the absence of ART; 2) Test novel and durable interventions targeting HIV infection; 3) Improve the treatment and prevention of drug sensitive and drug resistant tuberculosis; 4) Prevent or improve the treatment of HIV-related non-infectious co-morbidities and evaluate strategies to cure hepatitis B virus infection in people with and without HIV.

项目摘要 艾滋病临床试验小组(ACTG)一直站在推动艾滋病毒的临床研究的前沿 治疗和改善30年来艾滋病毒/艾滋病患者的健康。严谨的科学研究 ACTG开展的这项工作为目前的艾滋病毒治疗指南奠定了基础。在此应用程序中， ACTG的竞争性更新我们提出了一个变革性的研究议程，借鉴了 由领先的临床和实验室艾滋病毒研究人员组成的国际联盟，与世界级的 统计和数据管理中心设计和进行创新的介入临床试验，将 大大减少全球因艾滋病毒、结核病和乙肝造成的疾病负担。 领导力和运营中心(LOC)提供科学的领导力以及财务和组织 ACTG的管理。ACTG执行委员会(AEC)将作为最高管理机构 网络的主体。AEC由包括网络在内的执行管理委员会指导 主席、首席质量官以及实验室和统计及数据管理中心的主席。 变革性科学小组将监督ACTG研究议程的制定和执行， 将由科学议程指导委员会(SASC)协调和确定优先事项。协议 开发、实施、培训和网络评估将由网络临床核心促进，网址为 社会科学与科学系统公司。加州大学LOC财务管理小组(管理核心) 加州，洛杉矶将监督资源管理和礼宾基金的分配 AEC。LOC将确保社区参与ACTG的所有方面，并将协调 网络的所有三个组件之间的通信。该提案的具体目标包括：1)确定 在没有抗逆转录病毒疗法的情况下减少艾滋病毒宿主和控制艾滋病毒复制的干预措施；2)测试新的和 针对艾滋病毒感染的持久干预措施；3)改善对药物敏感和药物敏感的治疗和预防 耐药结核病；4)预防或改进艾滋病毒相关非传染性合并症的治疗和 评估在感染和未感染艾滋病毒的人群中治愈乙肝病毒感染的策略。